Peposertib Clinical Trials (2026): 14 Studies for Metastatic Malignant Solid Neoplasm & Unresectable Malignant Solid Neoplasm
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
14 Peposertib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 14 indications (including Metastatic Malignant Solid Neoplasm & Unresectable Malignant Solid Neoplasm) and 1,101 total planned enrollment. 7 Peposertib clinical trials are actively recruiting at 66 U.S. sites across 20 states. Most recent activity: NCT02813135 (Feb 2031).
Where to Participate: All Peposertib Trial Sites in the U.S. (66 sites across 20 states)
Every actively recruiting Peposertibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | City of Hope Comprehensive Cancer Center | Duarte91010 | NCT04071236 | Map |
| CA | City of Hope Comprehensive Cancer Center | Duarte91010 | NCT04172532 | Map |
| CA | City of Hope at Irvine Lennar | Irvine92618 | NCT04172532 | Map |
| CA | UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care | Irvine92612 | NCT04172532 | Map |
| CA | Los Angeles General Medical Center | Los Angeles90033 | NCT05711615 | Map |
| CA | USC / Norris Comprehensive Cancer Center | Los Angeles90033 | NCT05711615 | Map |
| CA | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange92868 | NCT04071236 | Map |
| CA | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange92868 | NCT04172532 | Map |
| CA | University of California Davis Comprehensive Cancer Center | Sacramento95817 | NCT04172532 | Map |
| CO | UCHealth University of Colorado Hospital | Aurora80045 | NCT05711615 | Map |
| CO | UCHealth University of Colorado Hospital | Aurora80045 | NCT04172532 | Map |
| DC | Sibley Memorial Hospital | Washington D.C.20016 | NCT04172532 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Aventura | Aventura33180 | NCT04071236 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Coral Gables | Coral Gables33146 | NCT04071236 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Deerfield Beach | Deerfield Beach33442 | NCT04071236 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Kendall | Miami33176 | NCT04071236 | Map |
| FL | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami33136 | NCT05711615 | Map |
| FL | University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami33136 | NCT04071236 | Map |
| FL | UM Sylvester Comprehensive Cancer Center at Plantation | Plantation33324 | NCT04071236 | Map |
| IL | University of Chicago Comprehensive Cancer Center | Chicago60637 | NCT05711615 | Map |
| IL | UC Comprehensive Cancer Center at Silver Cross | New Lenox60451 | NCT05711615 | Map |
| IL | University of Chicago Medicine-Orland Park | Orland Park60462 | NCT05711615 | Map |
| KS | University of Kansas Clinical Research Center | Fairway66205 | NCT04172532 | Map |
| KS | HaysMed | Hays67601 | NCT04172532 | Map |
| KS | University of Kansas Cancer Center | Kansas City66160 | NCT04172532 | Map |
| KS | Lawrence Memorial Hospital | Lawrence66044 | NCT04172532 | Map |
| KS | The University of Kansas Cancer Center - Olathe | Olathe66061 | NCT04172532 | Map |
| KS | University of Kansas Cancer Center-Overland Park | Overland Park66210 | NCT04172532 | Map |
| KS | Salina Regional Health Center | Salina67401 | NCT04172532 | Map |
| KS | University of Kansas Health System Saint Francis Campus | Topeka66606 | NCT04172532 | Map |
| KS | University of Kansas Hospital-Westwood Cancer Center | Westwood66205 | NCT04172532 | Map |
| KY | University of Kentucky/Markey Cancer Center | Lexington40536 | NCT04071236 | Map |
| MD | Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore21287 | NCT05711615 | Map |
| MD | National Cancer Institute Developmental Therapeutics Clinic | Bethesda20892 | NCT05687136 | Map |
| MD | National Cancer Institute Developmental Therapeutics Clinic | Bethesda20892 | NCT05711615 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT05687136 | Map |
| MA | Dana-Farber Cancer Institute | Boston02215 | NCT05711615 | Map |
| MA | Massachusetts General Hospital Cancer Center | Boston02114 | NCT05687136 | Map |
| MO | Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters63376 | NCT04071236 | Map |
| MO | Siteman Cancer Center at West County Hospital | Creve Coeur63141 | NCT04071236 | Map |
| MO | University Health Truman Medical Center | Kansas City64108 | NCT04172532 | Map |
| MO | University of Kansas Cancer Center - North | Kansas City64154 | NCT04172532 | Map |
| MO | University of Kansas Cancer Center - Lee's Summit | Lee's Summit64064 | NCT04172532 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT05711615 | Map |
| MO | Siteman Cancer Center-South County | St Louis63129 | NCT04071236 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT05711615 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT04071236 | Map |
| NJ | Saint Barnabas Medical Center | Livingston07039 | NCT04172532 | Map |
| NJ | Monmouth Medical Center | Long Branch07740 | NCT04172532 | Map |
| NJ | Rutgers Cancer Institute of New Jersey | New Brunswick08903 | NCT04172532 | Map |
| NY | NYU Langone Hospital - Long Island | Mineola11501 | NCT05687136 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center at NYU Langone | New York10016 | NCT05687136 | Map |
| NY | Mount Sinai Hospital | New York10029 | NCT04172532 | Map |
| NY | NYP/Weill Cornell Medical Center | New York10065 | NCT04172532 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT04071236 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT04071236 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT05711615 | Map |
| PA | University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh15232 | NCT04172532 | Map |
| TN | Vanderbilt University/Ingram Cancer Center | Nashville37232 | NCT04172532 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT04555577 | Map |
| TX | M D Anderson Cancer Center | Houston77030 | NCT05711615 | Map |
| UT | Huntsman Cancer Institute/University of Utah | Salt Lake City84112 | NCT04071236 | Map |
| VA | University of Virginia Cancer Center | Charlottesville22908 | NCT05711615 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT04172532 | Map |
| WI | University of Wisconsin Carbone Cancer Center - Eastpark Medical Center | Madison53718 | NCT04172532 | Map |
| WI | University of Wisconsin Carbone Cancer Center - University Hospital | Madison53792 | NCT04172532 | Map |
Peposertib clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | Total |
|---|---|---|---|---|
| P1 | 4 | 4 | 1 | 9 |
| P1/P2 | 3 | 1 | 1 | 5 |
Recruiting Peposertib clinical trials (7)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT02813135 | ESMARTEuropean Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors | P1/P2 | Pediatric Cancer | 472 | Aug 2016 |
| NCT04555577 | Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma | P1 | Glioblastoma | 29 | Sep 2020 |
| NCT04071236 | M3814Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy | P1/P2 | Metastatic Castration-Resistant Prostate Carcinoma | 90 | Oct 2020 |
| NCT05868174 | Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors | P1 | Solid Tumor, Adult | 36 | May 2023 |
| NCT05711615 | Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma | P1 | Metastatic Dedifferentiated Liposarcoma | 30 | Feb 2024 |
| NCT05687136 | M3814Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors | P1 | Advanced Malignant Solid Neoplasm | 66 | Jun 2024 |
| NCT04172532 | Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer | P1/P2 | Locally Advanced Pancreatic Adenocarcinoma | 92 | Jan 2021 |
Peposertib clinical trials by indication
Advanced Malignant Solid Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05687136 | M3814 | P1 | recruiting | Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors |
Metastatic Dedifferentiated Liposarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05711615 | — | P1 | recruiting | Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma |
Solid Tumor, Adult (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05868174 | — | P1 | recruiting | Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors |
Advanced Head and Neck Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04533750 | — | P1 | active not recruiting | Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin |
Neuroendocrine Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04750954 | — | P1 | active not recruiting | Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors |
Healthy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04702698 | — | P1 | completed | Effect of Food on Peposertib PK |
Locally Advanced Pancreatic Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04172532 | — | P1/P2 | recruiting | Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer |
Metastatic Castration-Resistant Prostate Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04071236 | M3814 | P1/P2 | recruiting | Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy |
Glioblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04555577 | — | P1 | recruiting | Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma |
Endometrial High Grade Endometrioid Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04092270 | M3814 | P1 | active not recruiting | A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer |
Recurrent Acute Myeloid Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03983824 | — | P1 | active not recruiting | Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia |
Locally Advanced Malignant Solid Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04068194 | — | P1/P2 | active not recruiting | Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies |
Locally Advanced Rectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03770689 | — | P1/P2 | completed | Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer |
Pediatric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02813135 | ESMART | P1/P2 | recruiting | European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors |
All Peposertib trials (14)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT02813135 | ESMART | European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors | P1/P2 | recruiting | 472 | Gustave Roussy, Cancer Campus, Grand Paris | Aug 2016 |
| NCT04555577 | Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma | P1 | recruiting | 29 | M.D. Anderson Cancer Center | Sep 2020 | |
| NCT04068194 | Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies | P1/P2 | active not recruiting | 103 | National Cancer Institute (NCI) | Apr 2020 | |
| NCT03983824 | Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia | P1 | active not recruiting | 48 | National Cancer Institute (NCI) | May 2020 | |
| NCT04071236 | M3814 | Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy | P1/P2 | recruiting | 90 | National Cancer Institute (NCI) | Oct 2020 |
| NCT05868174 | Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors | P1 | recruiting | 36 | Telix Pharmaceuticals (Innovations) Pty Limited | May 2023 | |
| NCT04533750 | Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin | P1 | active not recruiting | 21 | National Cancer Institute (NCI) | Dec 2021 | |
| NCT05711615 | Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma | P1 | recruiting | 30 | National Cancer Institute (NCI) | Feb 2024 | |
| NCT05687136 | M3814 | Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors | P1 | recruiting | 66 | National Cancer Institute (NCI) | Jun 2024 |
| NCT04172532 | Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer | P1/P2 | recruiting | 92 | National Cancer Institute (NCI) | Jan 2021 | |
| NCT04750954 | Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors | P1 | active not recruiting | 29 | National Cancer Institute (NCI) | Jul 2021 | |
| NCT04092270 | M3814 | A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer | P1 | active not recruiting | 54 | National Cancer Institute (NCI) | May 2020 |
| NCT03770689 | Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer | P1/P2 | completed | 19 | EMD Serono Research & Development Institute, Inc. | Mar 2019 | |
| NCT04702698 | Effect of Food on Peposertib PK | P1 | completed | 12 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Jan 2021 |
Peposertib clinical trials: frequently asked questions
- How many Peposertib clinical trials are there?
- 14 Peposertib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 7 are actively recruiting participants. 2 are marked completed.
- Are Peposertib clinical trials recruiting in 2026?
- Yes — 7 Peposertib trials are actively recruiting in 2026, with 66 U.S. sites across 20 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Peposertib being studied for?
- Peposertib is being studied for Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm, Advanced Laryngeal Squamous Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Oral Cavity Squamous Cell Carcinoma and 82 more. The trials are grouped by indication on this page.
- What phase is Peposertib in?
- Peposertib clinical trials span 9 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Peposertib clinical trials?
- The lead sponsor across the most Peposertib trials is National Cancer Institute (NCI), with 5 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Peposertibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: